Novozymes closes transaction of majority stake in Synergia Life Sciences

In Denmark, Novozymes A/S completed the acquisition of a majority stake in Synergia Life Sciences Pte. Ltd. as initially announced on November 30, 2021, following the fulfillment of all closing conditions. As a result of the acquisition, Novozymes is now the controlling shareholder in Synergia Life Sciences.

Synergia Life Sciences will be integrated into Novozymes’ human health activities and sales will be reported in the Food, Beverages & Human Health segment.

Novozymes takes the next significant step in accelerating into the fast-growing markets of human health and functional foods by entering into an agreement to acquire a majority stake in Synergia Life Sciences Pte. Ltd., a leading developer and manufacturer of spore probiotics and natural vitamin K2-7. Synergia Life Sciences has a global commercial footprint, three production sites in India, and 2021 pro forma sales (adjusted for Novozymes related sales), of around DKK 150 million and EBITDA/EBIT margins well above those of Novozymes.